Cutaneous leishmaniasis;Kutane leishmaniasis

Hautarzt

Volumn 58, Issue 5, 2007, Pages 445-459

  Von Stebut, E ^a   Sunderkotter C ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Intracellular parasite; Leishmaniasis; Oriental sore; Parasites; Th1 Th2 immunity

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; BENZENE DERIVATIVE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METHYLBENZONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; PETROLATUM; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

CRYOTHERAPY; DIFFERENTIAL DIAGNOSIS; ECTHYMA; ENDEMIC DISEASE; EXCISION; HUMAN; LEISHMANIA; LEISHMANIA AETHIOPICA; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; REVIEW; SKIN BIOPSY; SKIN CANCER; SKIN LEISHMANIASIS; SKIN ULCER;

EID: 34248364350     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-007-1327-8     Document Type: Review

References (34)

1. Alrajhi AA, Ibrahim EA, De Vol EB et al. (2002) Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346: 891-895
2. Asilian A, Davami M (2006) Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 31: 634-637
3. Belkaid Y, Blank RB, Suffia I (2006) Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol Rev 212: 287-300
4. Berhe N, Wolday D, Hailu A et al. (1999) HIV viral load and response to antileishmanial chemotherapy in co-infected patients. Aids 13: 1921-1925
5. Berman J (2005) Miltefosine to treat leishmaniasis. Expert Opin Pharmacother 6: 1381-1388
6. Blum J, Desjeux P, Schwartz E et al. (2004) Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53: 158-166
7. Bottrel R, Dutra W, Martins F et al. (2001) Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 69: 3232-3239
8. Bourreau E, Gardon J, Pradinaud R et al. (2003) The responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses. Infect Immun 71: 2244-2246
9. + T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis 193: 1313-1322
10. Desjeux, P (2001) The increase risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95: 239-243
11. El-On J, Bazarsky E, Sneir R (in press) Leishmania major: In vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. Exp Parasitol 30: Epub ahead of print
12. Gradoni L, Scalone A, Gramoccia M (1993) HIV-Leishmania co-infections in Italy: serological data as an indication of the sequence of acquisition of the two infections. Trans R Soc Trop Med Hyg 87: 94-96
13. Grevelink SA, Lerner EA (1996) Leishmaniasis. J Am Acad Dermatol 34: 257-272
14. Kane MM, Mosser DM (2001) The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166: 1141-1147
15. Kolde G, Luger T, Sorg C, Sunderkötter C (1996) Successful treatment of cutaneous leishmaniasis using interferon-gamma. Dermatology 192: 56-60
16. Lee SA, Hasbun R (2003) Therapy of cutaneous leishmaniasis. Int J Infect Dis 7: 86-93
17. Marques MJ, Volpini AC, Machado-Coelho GL et al. (2006) Comparison of polymerase chain reaction with other laboratory methods for the diagnosis of American cutaneous leishmaniasis: diagnosis of cutaneous leishmaniasis by polymerase chain reaction. Diagn Microbiol Infect Dis 54: 37-43
18. Martinez S, Marr JJ (1992) Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 326: 741-744
19. Modlin R (1994) Th1-Th2 paradigm: insights from leprosy. J Invest Dermatol 102: 828-832
20. Panagiotopoulos A, Stavropoulos PG, Hasapi V et al. (2005) Treatment of cutaneous leishmaniasis with cryosurgery. Int J Dermatol 44: 749-752
21. Reithinger R, Mohsen M, Aadil K et al. (2003) Anthroponotic cutaneous leishmaniasis, Kabul, Afghanistan. Emerg Infect Dis 9: 727-729
22. Reithinger R, Mohsen M, Wahid M et al. (2005) Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 40: 1148-1155
23. Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858
24. Schwartz E, Hatz C, Blum J (2006) New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 6: 342-392
25. Solomon M, Baum S, Barzilai A et al. (in press) Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol: Epub ahead of print
26. Sunderkötter C (im Druck) Hautinfektionen durch Parasiten. In: Marre R, Mertens T, Trautmann M, Zimmerli W (Hrsg) Klinische Infektiologie. 2. Aufl. Urban und Fischer, München
27. Sunderkötter C, Tomimori-Yamashita J, Nix V et al. (2004). High Expression of MRP8 and MRP14 characterizes an inflammatorily active but ineffective response of macrophages during leprosy. Immunology 111: 472-480
28. Turetz ML, Machado PR, Ko AI et al. (2002) Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 186: 1829-1834
29. Vardy D, Barenholz Y, Naftoliev N et al. (2001) Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Trans R Soc Trop Med Hyg 95: 184-186
30. Velez I, Agudelo S, Hendrickx E et al. (1997) Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126: 232-236
31. Stebut E von (2007) Cutaneous Leishmania infection: progress in pathogenesis research and experimental therapy. Exp Dermatol 16: 340-346
32. Stebut E von (2007) Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 17: 115-122
33. Woelbing F, Kostka SL, Moelle K et al. (2006) Uptake of Leishmania major by dendritic cells is mediated by Fc-gamma receptors and facilitates acquisition of protective immunity. J Exp Med. 203: 177-188
34. + T-cell activation-induced human immunodeficiency virus replication. Infect Immun 67: 5258-5264